The use of direct oral anticoagulants in inherited thrombophilia

@article{Skelley2016TheUO,
  title={The use of direct oral anticoagulants in inherited thrombophilia},
  author={Jessica W. Skelley and C. W. White and Angela R. Thomason},
  journal={Journal of Thrombosis and Thrombolysis},
  year={2016},
  volume={43},
  pages={24-30}
}
  • Jessica W. Skelley, C. W. White, Angela R. Thomason
  • Published 2016
  • Medicine
  • Journal of Thrombosis and Thrombolysis
    • To review the use of the direct oral anticoagulant (DOAC) agents in inherited thrombophilia based on the literature. MEDLINE, International Pharmaceutical Abstracts, and Google Scholar searches (1970–May 2016) were conducted for case reports, case series, retrospective cohorts, or clinical trials using the key words: protein C deficiency, protein S deficiency, antithrombin deficiency, activated protein C resistance, Factor V Leiden, hypercoagulable, NOACs, dabigatran, apixaban, rivaroxaban… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    39 Citations
    Background Citations
    17
    39 Citations
    Citation Type

    Citation Type

    Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study
    Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
    • 4
    • PDF
    Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report
    Direct Oral Anticoagulants
    Management of antithrombin deficiency: an update for clinicians
    • 4
    Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency
    • 5
    • PDF
    Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report
    • 4
    Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta‐analysis
    • 31
    Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    • 23
    The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period
    • 3
    • PDF

    References

    SHOWING 1-10 OF 53 REFERENCES
    Use of New Oral Anticoagulants in Antiphospholipid Syndrome
    • 57
    The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases.
    • 56
    New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.
    • 302
    • PDF
    Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
    • 460
    • PDF
    Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    • 82
    The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.
    • 94
    • PDF
    Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
    • 1,224
    Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™
    • 8
    Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
    • 375
    • PDF
    Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
    • 90